<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Paraneoplastic pemphigus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Paraneoplastic pemphigus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Paraneoplastic pemphigus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Grant J Anhalt, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John J Zone, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H22393518">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic pemphigus (PNP) is an often fatal paraneoplastic mucocutaneous blistering disease that is most commonly induced by lymphoproliferative disorders [
         <a href="#rid1">
          1
         </a>
         ]. Paraneoplastic autoimmune multiorgan syndrome (PAMS) is an alternative term used to refer to PNP. This latter term reflects the inclusion of the nonbullous cutaneous eruptions and pulmonary involvement that may develop in the setting of PNP [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The pathogenesis, clinical features, and treatment of PNP will be discussed here. Pemphigus vulgaris and pemphigus foliaceus are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of pemphigus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110145.html" rel="external">
          "Fogo selvagem (Brazilian endemic pemphigus foliaceus)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22393525">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although it is well-accepted that PNP is a rare disorder, the incidence and prevalence of PNP are unknown. The rarity of the disorder is supported by a review of 100,000 adverse events reports to the US Food and Drug Administration from patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia [
         <a href="#rid3">
          3
         </a>
         ]. The review identified only 12 patients who likely had the disease.
        </p>
        <p>
         Adults between the ages of 45 and 70 years constitute the most common demographic affected by PNP [
         <a href="#rid4">
          4
         </a>
         ]. However, the disorder may also occur in children [
         <a href="#rid5">
          5-7
         </a>
         ]. Both males and females may be affected.
        </p>
        <p>
         The frequency of PNP may be decreasing. In one academic medical center in the United States, the number of patients diagnosed with PNP fell from 22 between 2003 and 2010 to only 4 between 2011 and 2017 [
         <a href="#rid8">
          8
         </a>
         ]. Increased use of anti-CD20 monoclonal antibody therapy (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) for non-Hodgkin lymphoma and chronic lymphocytic leukemia may be a contributor. Theories include reduced recognition of PNP due to treatment-related alterations in the clinical presentation of PNP (suppression of B cell-mediated blistering) and a true reduction in incidence of PNP related to the early institution of effective treatment for malignancies responsive to this treatment [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22393532">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PNP occurs in association with a variety of neoplastic disorders [
         <a href="#rid9">
          9,10
         </a>
         ]. In a review of 163 cases of PNP reported between 1990 and 2003, the frequency of associated conditions was as follows [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-Hodgkin lymphoma (39 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic lymphocytic leukemia (18 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Castleman's disease (18 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carcinoma (9 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thymoma (6 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoma (6 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Waldenström's macroglobulinemia (1 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hodgkin lymphoma, monoclonal gammopathy, and melanoma (each &lt;1 percent)
        </p>
        <p>
        </p>
        <p>
         As illustrated in this study, lymphoproliferative diseases account for the vast majority of disorders associated with PNP. The sarcomas detected in patients with PNP include liposarcoma, leiomyosarcoma, reticulum cell sarcoma, and malignant nerve sheath tumors [
         <a href="#rid9">
          9
         </a>
         ]. Rare patients have tumors that are too poorly differentiated to define; these tumors are usually retroperitoneal and often have the characteristics of follicular dendritic cell sarcomas [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The distribution of PNP-associated neoplastic disorders may differ between children and the general population of patients with PNP. Castleman's disease is likely the most common associated disease in children. In a series of 14 children and adolescents with PNP, Castleman's disease was present in 12 patients (86 percent) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The time course for the development of PNP in relation to the underlying neoplastic disorder varies. In two-thirds of patients, the discovery of the neoplastic disorder precedes PNP [
         <a href="#rid12">
          12
         </a>
         ]. In our experience, the peak time for the development of PNP in patients with non-Hodgkin lymphoma is two to three years after diagnosis of the lymphoma. Although as many as 40 years have elapsed between Castleman's disease and the subsequent development of PNP, an interval of this length is highly unusual [
         <a href="#rid9">
          9
         </a>
         ]. Occasionally, the underlying neoplastic disorder is not identified prior to the death of the patient. In a series of 104 patients with clinical and immunologic findings consistent with PNP, 12 patients had no detectable tumor [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Immune checkpoint inhibitor therapy has been proposed as a contributory factor based upon case reports describing the development or exacerbation of PNP during
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         therapy for malignancy [
         <a href="#rid13">
          13,14
         </a>
         ]. However, an association has not been confirmed. (See
         <a class="medical medical_review" href="/z/d/html/128565.html" rel="external">
          "Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22393585">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several theories on the connection between neoplasms and PNP have been proposed. In general, it appears that the neoplastic process induces an autoimmune disorder in which both humoral and cell-mediated immune responses play significant roles [
         <a href="#rid2">
          2,15
         </a>
         ]. In an individual patient, the degree to which each type of immune response contributes to PNP may influence the clinical presentation of the disease.
        </p>
        <p class="headingAnchor" id="H2978471984">
         <span class="h2">
          Humoral immunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibodies against multiple epithelial antigens have been detected in PNP. The primary antigenic targets are desmoplakins, intracellular proteins that play an integral role in the anchoring of intermediate filaments to desmosomal plaques and in epidermal cell adhesion [
         <a href="#rid16">
          16
         </a>
         ]. The detection of antibodies against two desmoplakins (periplakin and envoplakin) are the most specific laboratory findings in PNP [
         <a href="#rid17">
          17,18
         </a>
         ]. (See
         <a class="local">
          'Other studies'
         </a>
         below.)
        </p>
        <p>
         Serum from affected patients can also contain antibodies against desmoplakin I, desmoplakin II, epiplakin, bullous pemphigoid antigen 1, plectin, and the protease inhibitor alpha-2-macroglobulin-like-1 (A2ML1) [
         <a href="#rid19">
          19,20
         </a>
         ]. Antibodies against desmoglein 3, a desmosomal protein targeted in pemphigus vulgaris, have also been identified in patients with PNP [
         <a href="#rid21">
          21
         </a>
         ]. In addition, rare cases of PNP in which antibodies against laminin 332 were detected in patients with follicular dendritic cell sarcoma have been reported [
         <a href="#rid22">
          22,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1714695443">
         <span class="h3">
          Antibody production
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathways that lead to the production and deposition of antibodies in the skin and mucous membranes in PNP are not well understood. Proposed mechanisms include the stimulation of antibody production by tumor-induced immune dysregulation as well as the occurrence of cross-reactivity between antibodies directed against tumor cells and epithelial antigens [
         <a href="#rid15">
          15
         </a>
         ]. Epitope spreading, a phenomenon in which tissue injury leads to the exposure of antigens normally hidden from the immune system, may also play a role [
         <a href="#rid15">
          15
         </a>
         ]. In such cases, a cutaneous cytotoxic or inflammatory reaction induced by the tumor could result in the immune detection of intracellular antigens in desmosomes and hemidesmosomes [
         <a href="#rid15">
          15,24
         </a>
         ].
        </p>
        <p>
         Although some authors have proposed that in certain lymphoproliferative disorders, antibody production by B lymphocytes may contribute to the development of PNP [
         <a href="#rid25">
          25,26
         </a>
         ], the relatively long period required for PNP resolution after the resection of Castleman's tumors (5 to 10 months) and the association of PNP with other malignancies, such as retroperitoneal sarcomas, reduce support for this concept as a major pathogenic mechanism. Moreover, in PNP related to Waldenström's macroglobulinemia, an IgM myeloma, the autoantibodies detected are polyclonal antibodies of the IgG class. This finding suggests an alternative source for antibody production [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1550867">
         <span class="h3">
          Pathogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have sought to clarify which antibodies, if any, are truly pathogenic in PNP. Although antibody deposition could stimulate the local recruitment of inflammatory cells and antibody-dependent cellular cytotoxicity, antibodies against epidermal components could also form as a secondary event following epidermal injury. A pathogenic role for antienvoplakin, antiperiplakin, and antidesmoglein 3 antibodies is suggested by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antienvoplakin and antiperiplakin antibodies can induce dissociation of cultured human epidermal keratinocytes in vitro [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Levels of antienvoplakin and antiperiplakin antibodies decreased as clinical improvement occurred following surgical removal of Castleman's tumors or thymoma in one small study [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Removal of antidesmoglein 3 antibodies from serum taken from PNP patients prior to the injection of the serum into neonatal mice prevented the development of blisters in mice [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, the contribution of these and other antibodies to the development of PNP remains uncertain. In particular, antidesmoglein 3 antibodies have not been essential for the induction of PNP in other animal models [
         <a href="#rid2">
          2
         </a>
         ], and normally, desmoglein 3 is not expressed by pulmonary epithelium, which can be affected in PNP [
         <a href="#rid29">
          29
         </a>
         ]. However, in one mouse model of PNP, lung inflammation produced ectopic expression of desmoglein 3 in the pulmonary epithelium [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H337056">
         <span class="h2">
          Cell-mediated immunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of cellular infiltrates and features consistent with interface or lichenoid dermatitis in tissue specimens taken from patients with PNP suggests that cellular immunity contributes to this disorder. In support of this concept, CD8+ cytotoxic T lymphocytes, CD56+ natural killer cells, and CD68+ monocytes and macrophages have been detected at the epidermal-dermal junction in affected patients [
         <a href="#rid2">
          2
         </a>
         ]. In addition, high levels of interleukin-6 (IL-6), a cytokine that promotes lymphocyte maturation, cytotoxic T cell activation, and antibody production, have been detected in patients with PNP [
         <a href="#rid31">
          31
         </a>
         ]. Increased local production of the proinflammatory cytokines interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha has also been reported in these patients [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Additional support for a role for cell-mediated immunity stems from the observation that cell-mediated cytotoxic reactions are seen in other skin diseases that clinically and histopathologically resemble PNP. Cutaneous graft-versus-host disease, lichen planus, and erythema multiforme can be difficult to distinguish clinically from PNP [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         below.)
        </p>
        <p>
         A cell-mediated immune reaction in the skin and mucous membranes may contribute to the stimulation of the humoral immune system. Inflammation-induced damage to the basal layer of the epithelium could result in the immune recognition of normally hidden epithelial antigens through epitope spreading. (See
         <a class="local">
          'Antibody production'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H7465407">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically, PNP is characterized by the following mucocutaneous and systemic features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe erosive stomatitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymorphous skin lesions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoreticular or other malignancies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary involvement with features of bronchiolitis obliterans (may or may not be present)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2749450708">
         <span class="h2">
          Mucosal lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic, erosive, progressive, and painful mucositis is uniformly present in patients with PNP, and in its absence, the diagnosis should not be considered. Oral involvement is most common [
         <a href="#rid10">
          10,18
         </a>
         ], and patients develop a painful, erosive stomatitis that characteristically includes involvement of the tongue (
         <a class="graphic graphic_picture graphicRef59594 graphicRef79518 graphicRef54382" href="/z/d/graphic/59594.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. Oral erosions are the initial disease manifestation in almost one-half of patients [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Other potential sites of mucosal involvement include the nasopharynx, conjunctiva, and anogenital area. Occasionally, lesions develop on the mucosal surfaces of the esophagus, stomach, duodenum, or colon [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         Mucosal involvement may lead to significant side effects. The pain associated with oral mucosal disease often inhibits oral intake, contributing to malnutrition. Conjunctival involvement may lead to cicatrizing conjunctivitis, damage to the cornea, and visual impairment [
         <a href="#rid35">
          35-37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H337116">
         <span class="h2">
          Cutaneous lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous lesions typically develop after the onset of mucosal lesions. The morphology of the cutaneous eruption is highly variable. Patients may present with bullae resembling the flaccid bullae of pemphigus vulgaris or the tense bullae of bullous pemphigoid, inflammatory violaceous papules or plaques resembling lichen planus or graft-versus-host disease, targetoid lesions similar to those of erythema multiforme or Stevens-Johnson syndrome, or extensive cutaneous desquamation resembling toxic epidermal necrolysis (
         <a class="graphic graphic_picture graphicRef67265 graphicRef79192 graphicRef62146" href="/z/d/graphic/67265.html" rel="external">
          picture 2A-C
         </a>
         ) [
         <a href="#rid10">
          10,12,18,38
         </a>
         ]. The cutaneous lesions of patients who develop PNP following treatment with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         may lack blistering and have more of a lichenoid or erythema multiforme-like appearance [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         More than one lesion type may occur simultaneously in individual patients. Less common cutaneous manifestations include psoriasiform, pustular, and vegetative lesions, as well as the development of alopecia or palmoplantar or periungual involvement [
         <a href="#rid6">
          6,15,40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H337139">
         <span class="h2">
          Pulmonary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PNP may develop a life-threatening restrictive bronchiolitis consistent with bronchiolitis obliterans. The frequency with which pulmonary involvement occurs is not well-defined. In one retrospective study of 17 patients with PNP, restrictive bronchiolitis was detected in three patients (18 percent) [
         <a href="#rid41">
          41
         </a>
         ]. In contrast, in a series of 28 patients with PNP related to Castleman's disease, pulmonary involvement was detected in 26 of 28 patients (93 percent) [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Bronchiolitis obliterans usually occurs late in the course of the disease and is heralded by the development of shortness of breath that is out of proportion to changes visualized on chest imaging. An obstructive pattern is evident on pulmonary function tests, and CT scans may demonstrate patchy or diffuse air trapping [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5735.html" rel="external">
          "Overview of pulmonary function testing in children"
         </a>
         .)
        </p>
        <p>
         The mechanism through which pulmonary damage occurs is not definitively known. Acantholysis, mixed inflammatory infiltrates, and antibody deposition have been detected in pulmonary epithelium in PNP [
         <a href="#rid29">
          29
         </a>
         ]. It has been suggested that pulmonary involvement results from the immune targeting of plakin proteins in the bronchial epithelium, resulting in detachment of cells and the occlusion of the distal alveolar sacs by cellular debris [
         <a href="#rid2">
          2
         </a>
         ]. CD8+ T lymphocytes may play an important role in pulmonary injury; a panmural infiltrate composed of CD8+ T lymphocytes was detected in a post-mortem examination of pulmonary tissue from a patient with PNP [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Antibodies against epiplakin may be markers for pulmonary involvement in PNP. In a series of 48 patients with PNP in Japan, antibodies against epiplakin were more prevalent in patients with associated bronchiolitis obliterans than patients without this condition [
         <a href="#rid20">
          20
         </a>
         ]. The finding that passive transfer of antiepiplakin antibodies into mice produces inflammatory changes in small airway epithelia suggests a possible pathogenic role for antiepiplakin antibodies [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H938432">
         <span class="h2">
          Other organs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibody deposition was detected in muscle, bladder, and renal glomeruli in a study of three patients with PNP [
         <a href="#rid2">
          2
         </a>
         ]. However, evidence for organ dysfunction related to these findings was not identified in these patients.
        </p>
        <p class="headingAnchor" id="H7465423">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H135452255">
         <span class="h2">
          Diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the variability in the clinical findings of PNP and the similarities between PNP and other disorders, the combined assessment of clinical and laboratory findings is necessary to establish the diagnosis. The key clinical findings that suggest PNP are the development of a painful erosive mucositis and polymorphous skin eruption in the setting of neoplastic disease. The laboratory studies used to support the diagnosis include light microscopy, direct immunofluorescence microscopy (DIF), and serologic studies that detect antibodies against epidermal proteins. (See
         <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">
          "Approach to the patient with cutaneous blisters", section on 'Diagnostic tests'
         </a>
         .)
        </p>
        <p>
         Our standard laboratory work-up for patients with suggestive clinical findings is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A lesional skin or mucosal biopsy for light microscopy (typically a 4 mm punch biopsy)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A perilesional punch biopsy specimen from skin or mucosa for DIF (specimen must not be placed in formalin)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum for indirect immunofluorescence (IIF) studies on monkey esophagus and rat bladder epithelium
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum for enzyme-linked immunosorbent assay (ELISA) for antienvoplakin and antiperiplakin antibodies
        </p>
        <p>
        </p>
        <p>
         Immunoprecipitation and immunoblotting are additional serologic tests that have been utilized for the diagnosis of PNP. However, the availability of these tests is limited, and these studies are not typically utilized in the clinical setting.
        </p>
        <p>
         Careful correlation of the clinical and laboratory findings is necessary for an accurate diagnosis of PNP because the histologic findings of PNP are not pathognomonic, and immunofluorescence studies and ELISA testing are sometimes negative. In particular, in patients who develop PNP after treatment with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , an anti-CD20 monoclonal antibody, autoantibodies may not be detectable in the epidermis or serum [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The laboratory studies used for the diagnosis of PNP are reviewed below.
        </p>
        <p class="headingAnchor" id="H653919">
         <span class="h3">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common histopathologic findings in PNP are suprabasal acantholysis (
         <a class="graphic graphic_picture graphicRef72907" href="/z/d/graphic/72907.html" rel="external">
          picture 3
         </a>
         ), keratinocyte necrosis, and a lichenoid interface dermatitis [
         <a href="#rid15">
          15,44
         </a>
         ]. However, the histopathologic findings vary, often resembling other disorders that have similar clinical features (see
         <a class="local">
          'Cutaneous lesions'
         </a>
         above) [
         <a href="#rid45">
          45
         </a>
         ]. For example, while acantholysis is typically a prominent feature in lesions that resemble pemphigus vulgaris, specimens taken from patients with tense bullae that resemble bullous pemphigoid may exhibit subepidermal clefting. Epidermal dyskeratosis, vacuolization of basal keratinocytes, and a lichenoid lymphocytic infiltrate are often found in cutaneous lesions that resemble lichen planus, erythema multiforme, or graft-versus-host disease [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Since the histologic findings overlap with multiple other disorders, correlation with the clinical scenario and other laboratory tests is important for diagnosis. The technique used to perform skin biopsies in blistering disorders is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">
          "Approach to the patient with cutaneous blisters", section on 'Skin biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H653956">
         <span class="h3">
          Direct immunofluorescence
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgG or C3 can be detected intercellularly and/or at the basement membrane zone on DIF microscopy in many cases of PNP (
         <a class="graphic graphic_picture graphicRef86800" href="/z/d/graphic/86800.html" rel="external">
          picture 4
         </a>
         ). However, negative DIF studies are not uncommon [
         <a href="#rid18">
          18,46
         </a>
         ]. In a study of 115 patients with PNP, pemphigus vulgaris, or pemphigus foliaceus, the sensitivity of DIF for PNP was only 41 percent [
         <a href="#rid18">
          18
         </a>
         ]. The specificity of the test was higher; when compared with patients with pemphigus vulgaris or pemphigus foliaceus who had (n = 12) or did not have (n = 81) a concurrent malignancy, the specificity of DIF was 83 and 93 percent, respectively. (See
         <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">
          "Approach to the patient with cutaneous blisters", section on 'Direct immunofluorescence'
         </a>
         .)
        </p>
        <p>
         The DIF findings of PNP can be similar to the findings of pemphigus vulgaris and pemphigus erythematosus. Pemphigus vulgaris is characterized by the presence of epithelial cell surface IgG and C3, and pemphigus erythematosus sometimes presents with both epithelial cell surface and basement membrane zone deposition of IgG and C3.
        </p>
        <p class="headingAnchor" id="H653926">
         <span class="h3">
          Indirect immunofluorescence
         </span>
         <span class="headingEndMark">
          —
         </span>
         IIF performed on rat bladder epithelium is particularly useful for differentiating PNP from pemphigus vulgaris. While both PNP and pemphigus vulgaris demonstrate epithelial cell surface deposits of IgG on monkey esophagus epithelium (
         <a class="graphic graphic_picture graphicRef86500" href="/z/d/graphic/86500.html" rel="external">
          picture 5
         </a>
         ), only PNP demonstrates this finding on rat bladder epithelium. This feature results from the absence of desmogleins (the target of antibodies in pemphigus vulgaris) in rat bladder epithelium.
        </p>
        <p>
         The transitional epithelium of murine (eg, rat) bladder is the preferred substrate for IIF studies in patients with PNP (
         <a class="graphic graphic_picture graphicRef86499" href="/z/d/graphic/86499.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. When performed on rat bladder epithelium, estimates for the sensitivity and specificity of this test have ranged from 74 to 86 percent and 83 to 100 percent, respectively [
         <a href="#rid18">
          18,46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">
          "Approach to the patient with cutaneous blisters", section on 'Indirect immunofluorescence'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H106809677">
         <span class="h3">
          Enzyme-linked immunosorbent assay
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enzyme-linked immunosorbent assays (ELISA) for antibodies against envoplakin and periplakin have been utilized in studies of patients with PNP [
         <a href="#rid17">
          17,48
         </a>
         ]. In one series of 16 patients with PNP, ELISA utilizing recombinant proteins derived from human kidney cells detected antibodies against envoplakin and periplakin in all patients [
         <a href="#rid17">
          17
         </a>
         ]. ELISA for desmoglein 3 was positive in 11 patients. In a separate study that evaluated serum from 31 patients with PNP and 80 controls, an ELISA based on the N-terminal fragment of envoplakin had a sensitivity and specificity for PNP of 81 and 99 percent, respectively; the ELISA for periplakin had a sensitivity and specificity of 74 and 96 percent [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H403244761">
         <span class="h3">
          Other studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunoprecipitation and immunoblotting are additional serologic tests that have been utilized for the diagnosis of PNP. However, the availability of these labor-intensive tests is limited to research laboratories and specialized centers. Thus, in clinical practice, immunoprecipitation and immunoblotting are not typically utilized for diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoprecipitation
         </strong>
         – The immunoprecipitation assay is considered to be more sensitive and specific than indirect immunofluorescence for diagnosis [
         <a href="#rid49">
          49
         </a>
         ]. The use of immunoprecipitation assays for the diagnosis of PNP involves the incubation of patient serum with radiolabeled keratinocyte proteins extracted from keratinocyte cultures [
         <a href="#rid42">
          42
         </a>
         ]. The antibody-antigen complexes that result are precipitated and analyzed via gel electrophoresis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A variety of immunoprecipitation bands have been detected in PNP, including plectin (&gt;400 kDa), desmoplakin I (250 kDa), bullous pemphigoid antigen 1 (230 kDa), envoplakin and desmoplakin II (a 210 kDa double band), periplakin (190 kDa), and alpha-2-macroglobulin-like-1 (A2ML1, 170 kDa) [
         <a href="#rid2">
          2,50
         </a>
         ]. The detection of periplakin and envoplakin or A2ML1 by immunoprecipitation is considered a highly specific laboratory finding of PNP [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The high sensitivity of immunoprecipitation for the diagnosis of PNP was demonstrated in a study of 19 patients with PNP (defined by consistent mucocutaneous findings, plakin autoantibodies, and an underlying neoplasm) and 40 controls that found sensitivities of antienvoplakin ELISA, rat bladder IIF, immunoblotting, radioactive immunoprecipitation, and a novel nonradioactive immunoprecipitation procedure of 63, 74, 89, 95, and 100 percent respectively [
         <a href="#rid47">
          47
         </a>
         ]. Specificities for these tests were 98, 100, 100, 100, and 86 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoblotting
         </strong>
         – In addition to immunoprecipitation, immunoblotting is another highly sensitive and specific method that has been used to detect autoantibodies in PNP [
         <a href="#rid18">
          18,47
         </a>
         ]. In a study of 115 patients with PNP, pemphigus vulgaris, and pemphigus foliaceus, the sensitivity of immunoblotting for envoplakin and/or periplakin for the diagnosis of PNP was 82 percent [
         <a href="#rid18">
          18
         </a>
         ]. The specificity of the immunoblot technique was 100 percent. Similar to immunoprecipitation, the availability of immunoblotting is limited.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H70116715">
         <span class="h2">
          Associated laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune cytopenias including thrombocytopenia, neutropenia, and autoimmune hemolytic anemia may be present as associated features. PNP patients may also develop clinical and serologic evidence of myasthenia gravis [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H337268">
         <span class="h2">
          Evaluation for the underlying disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         The selection of studies for the evaluation for an underlying cause in patients with PNP is based upon the spectrum of associated neoplasms. As examples, laboratory evaluation may identify hematologic disorders such as chronic lymphocytic leukemia or Waldenström's macroglobulinemia, while radiologic imaging can aid in the diagnosis of Castleman's disease and lymphomas.
        </p>
        <p>
         We typically perform the following evaluation [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thorough patient history and physical examination for signs suggestive of malignancy or lymphoproliferative disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum protein electrophoresis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT scan of the chest, abdomen, and pelvis
        </p>
        <p>
        </p>
        <p>
         As noted above, the vast majority of cases in children and adolescents are associated with Castleman's disease [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H70118251">
         <span class="h2">
          Evaluation for pulmonary involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because pulmonary involvement in PNP is typically accompanied by dyspnea, an evaluation for pulmonary involvement can be reserved for symptomatic patients. At the initial signs of shortness of breath or dyspnea on exertion, we refer patients to a pulmonologist for further evaluation. (See
         <a class="local">
          'Pulmonary disease'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H337194">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the wide variety of clinical findings that occur in PNP, the differential diagnosis is broad. Oral mucosal lesions must be differentiated from chemotherapy-associated mucositis and the multiple other blistering disorders that may affect mucosal surfaces (see
         <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">
          "Approach to the patient with cutaneous blisters", section on 'Mucous membrane involvement'
         </a>
         ). In patients with widespread blisters and erosions, the possibility of pemphigus vulgaris and subepidermal autoimmune blistering disorders (eg, bullous pemphigoid, epidermolysis bullosa acquisita) should be considered (see
         <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">
          "Approach to the patient with cutaneous blisters", section on 'Generalized distribution'
         </a>
         ). Papular lesions of PNP can resemble lichenoid drug eruptions and lichen planus. (See
         <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">
          "Lichenoid drug eruption (drug-induced lichen planus)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">
          "Lichen planus"
         </a>
         .)
        </p>
        <p>
         In addition to correlation of the mucocutaneous lesions with pathologic and serologic studies, knowledge of the chronic, progressive course of PNP is useful for diagnosis. Although similar mucocutaneous lesions may occur in erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, the acute nature of these disorders (improvement usually attained within three to five weeks) distinguishes them from PNP. (See
         <a class="local">
          'Prognosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">
          "Erythema multiforme: Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7465430">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of patients with PNP consists of the suppression of the disease manifestations and the management of patient symptoms. Treatment of the underlying malignancy is beneficial in some cases.
        </p>
        <p class="headingAnchor" id="H337229">
         <span class="h2">
          Treatment of the underlying neoplasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         In PNP associated with Castleman's disease or thymoma, resection of the tumor often results in disease remission. In one series of five adults with Castleman's disease and PNP, significant improvement in mucosal lesions and resolution of skin lesions occurred in all four patients who returned for a follow-up visit six months after surgery [
         <a href="#rid52">
          52
         </a>
         ]. However, remission may take up to one to two years to occur, and the disease persists after resection in some cases [
         <a href="#rid42">
          42,53
         </a>
         ].
        </p>
        <p>
         In PNP associated with other neoplastic disorders, the response of PNP to treatment of the underlying neoplasm appears to be less favorable. Once initiated, PNP often progresses independent of the status of the underlying neoplastic disease [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H337237">
         <span class="h2">
          Suppression of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the rarity of PNP, no randomized therapeutic trials have been performed and efficacy data are primarily limited to case reports. The response to treatment is highly variable. Refractory PNP, particularly refractory stomatitis, is common [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H278791">
         <span class="h3">
          Conventional immunosuppressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoids are often the initial treatments attempted in patients with PNP [
         <a href="#rid12">
          12,46,53
         </a>
         ]. High-dose regimens, usually beginning with 1 mg/kg per day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         followed by a slow taper as tolerated are used [
         <a href="#rid12">
          12
         </a>
         ]. We typically taper patients to a maintenance dose of 10 to 15 mg of prednisone per day over the course of six months. The cutaneous manifestations are more likely to respond to systemic glucocorticoids than the oral mucosal lesions; the latter are often refractory to therapy [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Other immunosuppressive agents are often combined with systemic glucocorticoids in attempts to attain further clinical improvement or to take advantage of their glucocorticoid-sparing effects.
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         [
         <a href="#rid54">
          54,55
         </a>
         ],
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil [
         <a href="#rid56">
          56
         </a>
         ],
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [
         <a href="#rid57">
          57,58
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid59">
          59
         </a>
         ] have been reported to be beneficial in individual patients [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H278801">
         <span class="h3">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple case reports have described the use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , a chimeric antibody that targets CD20 on B lymphocytes, in patients with PNP associated with various neoplastic disorders [
         <a href="#rid60">
          60
         </a>
         ]. Patients have been treated with various regimens, including 375 mg/m
         <sup>
          2
         </sup>
         of rituximab administered on a weekly basis for four weeks with or without subsequent less frequent doses [
         <a href="#rid60">
          60-62
         </a>
         ].
        </p>
        <p>
         The response to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         therapy is highly variable. A review of 13 reported cases of PNP that were treated with rituximab found complete responses in three patients, all of whom had non-Hodgkin lymphoma [
         <a href="#rid60">
          60
         </a>
         ]. The limited efficacy of rituximab may reflect the fact that the drug reduces autoantibody levels but has a lesser effect on regulation of cell-mediated immunity. In one patient, rituximab improved the blistering mucocutaneous lesions but failed to prevent the progression of fatal bronchiolitis obliterans [
         <a href="#rid63">
          63
         </a>
         ]. Further study is necessary to definitively determine the role rituximab should play in PNP.
        </p>
        <p class="headingAnchor" id="H278823">
         <span class="h3">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individual patients, plasmapheresis [
         <a href="#rid64">
          64
         </a>
         ], myeloablation with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid65">
          65
         </a>
         ], intravenous immunoglobulin (
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ) [
         <a href="#rid25">
          25,66
         </a>
         ],
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         [
         <a href="#rid67">
          67,68
         </a>
         ], and daclizumab [
         <a href="#rid39">
          39
         </a>
         ] have been reported to be effective in combination with other therapeutic interventions. Topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         in a 0.03% suspension used to rinse the mouth three times daily for six weeks was associated with improvement in a relapse of oral involvement in a patient with PNP due to non-Hodgkin lymphoma [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H937917">
         <span class="h3">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definitive guidelines for the management of PNP have not been established. We have found the following approach most useful:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Define and treat the underlying neoplasm (particularly useful in Castleman's disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-line therapy
         </strong>
         – Administer
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (1 mg/kg) in an attempt to provide acute improvement in mucocutaneous manifestations; initiate
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         as soon as feasible (375 mg/m
         <sup>
          2
         </sup>
         weekly for four weeks and repeat this course every three to six months); taper prednisone slowly as tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who improve only partially with the regimen above or who develop disease flares during
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         tapering, we typically add an immunosuppressive agent, either
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (1000 mg twice daily) or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (up to 3 mg/kg per day; dose adjustments may be made according to thiopurine methyltransferase [TPMT] activity). We generally avoid
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         due to concerns regarding the consequences of profound immunosuppression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (2 g/kg given as 0.67 g/kg per day for three days and repeated monthly as needed) can be added to the therapeutic regimen to provide an additional immunomodulatory effect without increasing the level of overall immunosuppression.
        </p>
        <p>
        </p>
        <p>
         We have observed positive responses to the nondepleting anti-CD25 monoclonal antibody daclizumab in patients who have failed to improve with the above measures, particularly in patients with progressive pulmonary involvement. However, daclizumab is no longer commercially available. We do not have experience with
         <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">
          basiliximab
         </a>
         , an agent with a similar mechanism of action.
        </p>
        <p>
         Of note, the decision to initiate immunomodulatory therapy in the setting of PNP should be made in conjunction with the patient's oncologist.
        </p>
        <p class="headingAnchor" id="H938323">
         <span class="h2">
          Adjunctive measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the fact that PNP may be difficult to treat, management of patient symptoms is also an important component of patient management. Anesthetic mouthwashes can be attempted for oral pain, but often do not help significantly, and narcotic pain medications may be necessary. Vaseline gauze can be applied to cutaneous erosions. For patients with extensive cutaneous erosions, such as patients with a toxic epidermal necrolysis-like presentation, admission to a burn unit facilitates patient management and wound care.
        </p>
        <p>
         Given the extent of immunosuppressive therapy often required for the management of PNP, the need for prophylaxis against Pneumocystis pneumonia should be evaluated. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7465437">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PNP has traditionally been thought to have a very poor prognosis, with most patients dying within two years [
         <a href="#rid29">
          29,46
         </a>
         ]. Affected patients usually succumb to sepsis, respiratory failure due to pulmonary involvement, or the underlying malignancy [
         <a href="#rid10">
          10,11,46
         </a>
         ]. However, a French multicenter retrospective study of 53 patients with PNP who received a variety of therapies suggested that the prognosis of PNP may be better [
         <a href="#rid46">
          46
         </a>
         ]. The respective one, three, and five-year overall survival rates were 49, 41, and 38 percent. Patients with erythema multiforme-like skin lesions, particularly in the context of severe skin or mucosal involvement appeared to have the worst prognosis. A separate review of 144 adults with hematologic malignancy-associated PNP found a one-year survival rate of 62 percent; toxic epidermal necrolysis-like PNP and PNP associated with bronchiolitis obliterans were associated with a particularly poor prognosis [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Pulmonary disease often fails to improve despite successful treatment of the malignancy and the resolution of mucocutaneous lesions [
         <a href="#rid4">
          4,41
         </a>
         ]. Lung transplantation was used for the management of an adolescent with pulmonary involvement related to Castleman's disease [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2748212827">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/132082.html" rel="external">
          "Society guideline links: Pemphigus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H938557">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Paraneoplastic pemphigus (PNP) is a rare autoimmune blistering disorder that may occur in the setting of lymphoproliferative disorders and malignancies. Although adults are most commonly affected, PNP may also occur in children. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – Multiple malignant and lymphoproliferative disorders are associated with PNP. The disorders most frequently linked to PNP are non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Castleman's disease. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The pathophysiology of PNP is not well understood. It is likely that both the humoral and cellular immune system contribute significantly to this disease. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antibodies against periplakin and envoplakin are strongly associated with PNP. A pathogenic role for these and the multiple other antibodies detected in patients with PNP remains uncertain. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The clinical manifestations of PNP vary widely. Mucosal involvement occurs in all patients, with oral involvement being the most common site for involvement (
         <a class="graphic graphic_picture graphicRef59594 graphicRef79518 graphicRef54382" href="/z/d/graphic/59594.html" rel="external">
          picture 1A-C
         </a>
         ). The most common cutaneous manifestations are flaccid or tense bullae, lichenoid papules or plaques, targetoid lesions, and erosions (
         <a class="graphic graphic_picture graphicRef67265 graphicRef79192" href="/z/d/graphic/67265.html" rel="external">
          picture 2A-B
         </a>
         ). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary involvement
         </strong>
         – A restrictive bronchiolitis consistent with bronchiolitis obliterans occurs in a minority of patients with PNP. Pulmonary involvement can be life-threatening. (See
         <a class="local">
          'Pulmonary disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – PNP shares clinical and pathologic features with multiple other disorders. Confirmation of a diagnosis of PNP requires the correlation of clinical, pathologic, and immunologic studies. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Data are limited on therapies for PNP. Surgical removal of the underlying tumor can be beneficial in patients with Castleman's disease or thymoma but is much less likely to be of value for other malignancies. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with PNP, we suggest the use of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         as first-line therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If this is not effective, additional therapies such as
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , and intravenous immunoglobulin can be added as adjunctive therapy. (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001; 137:193.
          </a>
         </li>
         <li class="breakAll">
          Anhalt GJ, Mimouni D. Paraneoplastic pemphigus. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest, BA, et al. (Eds), McGraw Hill, 2012. Vol 1, p.600.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol 2011; 50:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane JE, Woody C, Davis LS, et al. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature. Pediatrics 2004; 114:e513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han SP, Fu LS, Chen LJ. Masked pemphigus among pediatric patients with Castleman's disease. Int J Rheum Dis 2019; 22:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwatra SG, Boozalis E, Pasieka H, Anhalt GJ. Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies. Br J Dermatol 2019; 180:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan I, Hodak E, Ackerman L, et al. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004; 40:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohzono A, Sogame R, Li X, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol 2015; 173:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997; 12:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 2009; 48:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yatim A, Bohelay G, Grootenboer-Mignot S, et al. Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. Front Med (Lausanne) 2019; 6:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNally MA, Vangipuram R, Campbell MT, et al. Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma. JAAD Case Rep 2021; 10:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006; 39:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oursler JR, Labib RS, Ariss-Abdo L, et al. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest 1992; 89:1775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Y, Li J, Zhu X. Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus. Arch Dermatol Res 2009; 301:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000; 43:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numata S, Teye K, Tsuruta D, et al. Anti-α-2-macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. J Invest Dermatol 2013; 133:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchisaka A, Numata S, Teye K, et al. Epiplakin Is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans in Japanese Patients. J Invest Dermatol 2016; 136:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amagai M, Nishikawa T, Nousari HC, et al. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998; 102:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiura K, Koga H, Ishikawa R, et al. Paraneoplastic pemphigus with anti-laminin-332 autoantibodies in a patient with follicular dendritic cell sarcoma. JAMA Dermatol 2013; 149:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada H, Nobeyama Y, Matsuo K, et al. A case of paraneoplastic pemphigus associated with triple malignancies in combination with antilaminin-332 mucous membrane pemphigoid. Br J Dermatol 2012; 166:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen GM, Peters NT, Fivenson DP, et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol 2000; 136:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol 2007; 34:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Bu DF, Li T, et al. Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br J Dermatol 2005; 153:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perera GK, Devereux S, Mufti G, et al. PNP with Waldenström's macroglobulinaemia. Clin Exp Dermatol 2005; 30:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Bu DF, Huang YC, Zhu XJ. Role of autoantibodies against the linker subdomains of envoplakin and periplakin in the pathogenesis of paraneoplastic pemphigus. Chin Med J (Engl) 2009; 122:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340:1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hata T, Nishimoto S, Nagao K, et al. Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus. J Immunol 2013; 191:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousari HC, Kimyai-Asadi A, Anhalt GJ. Elevated serum levels of interleukin-6 in paraneoplastic pemphigus. J Invest Dermatol 1999; 112:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reich K, Brinck U, Letschert M, et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol 1999; 141:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakahara M, Kiyohara T, Kumakiri M, et al. Paraneoplastic pemphigus with widespread mucosal involvement. Acta Derm Venereol 2005; 85:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miida H, Kazama T, Inomata N, et al. Severe gastrointestinal involvement in paraneoplastic pemphigus. Eur J Dermatol 2006; 16:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beele H, Claerhout I, Kestelyn P, et al. Bilateral corneal melting in a patient with paraneoplastic pemphigus. Dermatology 2001; 202:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuero AE, Jakobiec FA, Bhat P, et al. Paraneoplastic conjunctival cicatrization: two different pathogenic types. Ophthalmology 2010; 117:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tam PM, Cheng LL, Young AL, Lam PT. Paraneoplastic pemphigus: an uncommon cause of chronic cicatrising conjunctivitis. BMJ Case Rep 2009; 2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin 2011; 29:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol 2007; 56:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. Australas J Dermatol 2005; 46:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology 2009; 14:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 2003; 149:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman MA, Qiao X, Anhalt GJ. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman's disease. N Engl J Med 2003; 349:407.
          </a>
         </li>
         <li class="breakAll">
          Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier, 2010. p.123.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol 1992; 128:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol 2012; 148:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poot AM, Diercks GF, Kramer D, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013; 169:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Probst C, Schlumberger W, Stöcker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010; 5:e12250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang R, Li J, Wang M, et al. Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis. Br J Dermatol 2015; 172:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang Y, Zhao L, Yan F, et al. A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman's disease. Med Oncol 2010; 27:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin 2011; 29:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hertzberg MS, Schifter M, Sullivan J, Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker LR, Bastian BC, Wesselmann U, et al. Paraneoplastic pemphigus treated with dexamethasone/ cyclophosphamide pulse therapy. Eur J Dermatol 1998; 8:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krunic AL, Kokai D, Bacetic B, et al. Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption. Int J Dermatol 1997; 36:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camisa C, Helm TN, Liu YC, et al. Paraneoplastic pemphigus: a report of three cases including one long-term survivor. J Am Acad Dermatol 1992; 27:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gergely L, Váróczy L, Vadász G, et al. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol 2003; 109:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anan T, Shimizu F, Hatano Y, et al. Paraneoplastic pemphigus associated with corneal perforation and cutaneous alternariosis: a case report and review of cases treated with rituximab. J Dermatol 2011; 38:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang H, Hu B, Chen H, et al. Therapy of paraneoplastic pemphigus with Rituximab: A case report. Dermatol Ther 2021; 34:e15144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viswanath V, Tare D, Patil PC. Successful use of intravenous and intralesional rituximab in paraneoplastic pemphigus with Castleman's disease. Int J Dermatol 2021; 60:e352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirano T, Higuchi Y, Yuki H, et al. Rituximab Monotherapy and Rituximab-Containing Chemotherapy Were Effective for Paraneoplastic Pemphigus Accompanying Follicular Lymphoma, but not for Subsequent Bronchiolitis Obliterans. J Clin Exp Hematop 2015; 55:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izaki S, Yoshizawa Y, Kitamura K, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol 1996; 134:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousari HC, Brodsky RA, Jones RJ, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999; 40:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanda M, Nanda A, Al-Sabah H, et al. Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Int J Dermatol 2007; 46:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohwy T, Bang K, Steiniche T, et al. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur J Haematol 2004; 73:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bech R, Baumgartner-Nielsen J, Peterslund NA, et al. Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. Br J Dermatol 2013; 169:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vecchietti G, Kerl K, Hügli A, et al. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br J Dermatol 2003; 148:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouedraogo E, Gottlieb J, de Masson A, et al. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. J Am Acad Dermatol 2019; 80:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chin AC, Stich D, White FV, et al. Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: A rare case of Castleman's disease with respiratory failure requiring lung transplantation. J Pediatr Surg 2001; 36:E22.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15305 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2247105" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176692" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176692" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21781058" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Paraneoplastic autoimmune multiorgan syndrome: 20 years after.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12366419" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Paraneoplastic pemphigus in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15466078" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30411519" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Masked pemphigus among pediatric patients with Castleman's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30648258" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15063382" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26358412" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical and immunological findings in 104 cases of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8973736" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19200194" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31750309" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33778141" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17101506" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1601988" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Human autoantibodies against desmoplakins in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18820940" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11004616" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23407400" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Anti-α-2-macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26802236" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epiplakin Is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans in Japanese Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9710446" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23324777" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Paraneoplastic pemphigus with anti-laminin-332 autoantibodies in a patient with follicular dendritic cell sarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21777224" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A case of paraneoplastic pemphigus associated with triple malignancies in combination with antilaminin-332 mucous membrane pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10815859" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17683379" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16120143" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663497" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : PNP with Waldenström's macroglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19323896" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Role of autoantibodies against the linker subdomains of envoplakin and periplakin in the pathogenesis of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10228191" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The mechanism of respiratory failure in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23729442" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084324" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Elevated serum levels of interleukin-6 in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10583130" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16396806" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Paraneoplastic pemphigus with widespread mucosal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16935802" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Severe gastrointestinal involvement in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11306844" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Bilateral corneal melting in a patient with paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20045572" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Paraneoplastic conjunctival cicatrization: two different pathogenic types.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21998619" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Paraneoplastic pemphigus: an uncommon cause of chronic cicatrising conjunctivitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21605807" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17097371" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15670168" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Paraneoplastic pemphigus: a brief update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144057" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14674890" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Paraneoplastic pemphigus in association with Castleman's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12878753" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12878753" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1497365" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Histologic features of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22801794" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prognostic factors of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23796242" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Laboratory diagnosis of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19737550" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14870982" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20805888" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25388377" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19763912" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A critical role of surgery in the treatment for paraneoplastic pemphigus caused by localized Castleman's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21925005" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10629583" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9889426" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Paraneoplastic pemphigus treated with dexamethasone/ cyclophosphamide pulse therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10735959" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9268753" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1401305" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Paraneoplastic pemphigus: a report of three cases including one long-term survivor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12853695" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21434987" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Paraneoplastic pemphigus associated with corneal perforation and cutaneous alternariosis: a case report and review of cases treated with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34582076" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Therapy of paraneoplastic pemphigus with Rituximab: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33720390" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Successful use of intravenous and intralesional rituximab in paraneoplastic pemphigus with Castleman's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26490520" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Rituximab Monotherapy and Rituximab-Containing Chemotherapy Were Effective for Paraneoplastic Pemphigus Accompanying Follicular Lymphoma, but not for Subsequent Bronchiolitis Obliterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8736359" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10321604" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17614814" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15287918" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23517368" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752158" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30981429" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11733934" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: A rare case of Castleman's disease with respiratory failure requiring lung transplantation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
